Ipragliflozin in the treatment of comorbid patients with type 2 diabetes mellitus

To date, according to the federal register of diabetes mellitus, 4.84 million patients with diabetes mellitus and 4.47 million of them have type 2 diabetes mellitus (T2DM). This is almost 92.4% of cases. Also, according to register, it is known that only two thirds of patients adopt the antidiabetic therapy recommended them. Often the patient already receives multicomponent treatment to which antidiabetic drugs are added, since most have at least several other concomitant pathologies, such as arterial hypertension, ischemic heart disease, obesity, dyslipidemia, chronic kidney disease. Both these states and many others determine the comorbide picture of the disease, when selecting medication therapy, it is necessary to be guided not only by direct, but also the playiotropic effects of the prescribed drugs. In this regard, the drugs security profile is a significant moment when choosing an antidiabetic preparation. Equally, the personalized selection of the drug is based on Russian and international algorithms for the maintenance of such patients. The inhibitors of of sodium-glucose cotransporter type 2 (SGLT2) inhibitors are an innovative class of antihyperglycemic drugs that demonstrate positive effects not only for their intended purpose - improving the glycemic profile with a low risk of hypoglycemic events, but also have a variety of non-glycemic effects, such as weight loss, normalization of blood pressure, reduction of proteinuria and, as a consequence, an increase in the quality of life. It is noteworthy that SGLT2 inhibitors showed an improvement not only in the risks of cardiovascular and renal outcomes, but also in mortality from any cause [1]. The use of this group of drugs is promising not only from the point of view of normalization of carbohydrate exchange indicators, but also as the prevention of micro- and macrovascular complications of T2DM. The economic feasibility of increasing the frequency of application of this group of drugs deserves separate attention. The published data of the pharmacoeconomic analysis of the use of ipragliflozin for the treatment of T2DM indicate a significant cost reduction within the budget of the State guarantees of free provision of medical care to citizens, on the basis of which ipragliflozin was included in the list of vital and essential drugs [2].

type 2 diabetes mellitus, T2DM, inhibitors of sodium-glucose co-transporter type 2, iSGLT2, ipragliflozin